Novavax (NASDAQ:NVAX) Stock Price Down 8.8% – Should You Sell?

Novavax, Inc. (NASDAQ:NVAX)’s stock price traded down 8.8% during mid-day trading on Monday . The company traded as low as $7.32 and last traded at $7.29. 2,424,248 shares traded hands during trading, a decline of 44% from the average session volume of 4,300,247 shares. The stock had previously closed at $7.99.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $19.00 price objective on shares of Novavax in a report on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $17.83.

Novavax Stock Up 2.1 %

The company’s fifty day moving average price is $8.58 and its 200 day moving average price is $10.04. The company has a market capitalization of $1.17 billion, a P/E ratio of -3.24, a PEG ratio of 2.85 and a beta of 2.14.

Insiders Place Their Bets

In related news, Director James F. Young sold 4,600 shares of the company’s stock in a transaction dated Tuesday, December 24th. The shares were sold at an average price of $8.48, for a total transaction of $39,008.00. Following the completion of the sale, the director now owns 57,160 shares of the company’s stock, valued at $484,716.80. This represents a 7.45 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Rachel K. King sold 4,150 shares of the firm’s stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $9.02, for a total transaction of $37,433.00. Following the completion of the transaction, the director now directly owns 14,770 shares in the company, valued at approximately $133,225.40. This represents a 21.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 14,150 shares of company stock worth $119,641 in the last 90 days. Company insiders own 1.00% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. acquired a new stake in shares of Novavax in the 4th quarter valued at $27,000. Spire Wealth Management acquired a new position in shares of Novavax during the 4th quarter worth $29,000. New Age Alpha Advisors LLC bought a new stake in shares of Novavax during the 4th quarter worth $35,000. KBC Group NV boosted its stake in Novavax by 97.0% in the fourth quarter. KBC Group NV now owns 7,954 shares of the biopharmaceutical company’s stock valued at $64,000 after buying an additional 3,917 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in Novavax by 38.1% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,790 shares of the biopharmaceutical company’s stock valued at $77,000 after acquiring an additional 1,598 shares during the last quarter. 53.04% of the stock is currently owned by institutional investors and hedge funds.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.